Alnylam Surpasses Wall Street Expectations with Fourth Quarter and Full-Year 2022 Results
Alnylam Pharmaceuticals Inc. (ALNY) reported strong financial results for the fourth quarter and full year of 2022.
Fourth Quarter Highlights:
* Loss of $83.8 million, exceeding analysts' expectations of a $83.8 million loss.
* Adjusted earnings per share of 6 cents, surpassing estimates of 21 cents per share.
* Revenue of $593.2 million, outperforming forecasts of $570.1 million.
Full-Year Highlights:
* Loss narrowed to $278.2 million, or $2.18 per share.
* Revenue reached $2.25 billion.
Alnylam's shares have experienced significant growth in recent months, with a 13% increase since the beginning of the year and a 57% increase in the past 12 months.